Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizu...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Pavord, I, Chanez, P, Criner, G, Kerstjens, H, Korn, S, Lugogo, N, Martinot, J, Sagara, H, Albers, F, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S, Sciurba, F
Format:	Journal article
Język:	English
Wydane:	Massachusetts Medical Society 2017

Podobne zapisy

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
od: Pavord, I, i wsp.
Wydane: (2017)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
od: Bafadhel, M, i wsp.
Wydane: (2018)

Mepolizumab for eosinophilic COPD
od: Sciurba, F, i wsp.
Wydane: (2018)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
od: Chapman, K, i wsp.
Wydane: (2018)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
od: Gunsoy, N, i wsp.
Wydane: (2017)

Mepolizumab treatment in patients with severe eosinophilic asthma.
od: Ortega, H, i wsp.
Wydane: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
od: Bel, E, i wsp.
Wydane: (2014)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
od: Shrimanker, R, i wsp.
Wydane: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
od: Mkorombindo T, i wsp.
Wydane: (2019-08-01)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
od: Pavord, I, i wsp.
Wydane: (2012)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
od: Bel, E, i wsp.
Wydane: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
od: Steven W. Yancey, i wsp.
Wydane: (2019-09-01)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
od: Ortega, H, i wsp.
Wydane: (2016)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
od: Yancey, S, i wsp.
Wydane: (2016)

Mepolizumab in refractory eosinophilic asthma.
od: Pavord, I, i wsp.
Wydane: (2010)

Mepolizumab, quality of life, and severe eosinophilic asthma.
od: Pavord, I
Wydane: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
od: Howell, I, i wsp.
Wydane: (2024)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
od: Prazma CM, i wsp.
Wydane: (2021-06-01)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
od: Ian D. Pavord, i wsp.
Wydane: (2022-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
od: Imran Howell, i wsp.
Wydane: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
od: Terufumi Shimoda, i wsp.
Wydane: (2017-07-01)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
od: Wechsler, M, i wsp.
Wydane: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
od: Moran, AM, i wsp.
Wydane: (2020)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
od: Haldar, P, i wsp.
Wydane: (2009)

Response to mepolizumab treatment is sustained across 4-weekly dosing periods
od: Ian D. Pavord, i wsp.
Wydane: (2020-09-01)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
od: Mi-Kyeong Kim, i wsp.
Wydane: (2021-03-01)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
od: Frank C. Albers, i wsp.
Wydane: (2019-07-01)

Treatment of eosinophilic myositis with mepolizumab
od: Saadia Waheed, i wsp.
Wydane: (2018-01-01)

GLUCOLD, eosinophils and chronic obstructive pulmonary disease
od: Pavord, I
Wydane: (2018)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
od: Shrimanker, R, i wsp.
Wydane: (2017)

Biomarkers for severe eosinophilic asthma.
od: Yancey, S, i wsp.
Wydane: (2017)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
od: Menzella F, i wsp.
Wydane: (2016-06-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
od: Shrimanker, R, i wsp.
Wydane: (2017)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
od: Moran, A, i wsp.
Wydane: (2020)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
od: Benjamin Terrier, i wsp.
Wydane: (2023-07-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
od: Chio Sakai, i wsp.
Wydane: (2024-07-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
od: Nina B. Curkovic, MD, i wsp.
Wydane: (2024-11-01)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
od: Ravi Ranjan Pradhan, i wsp.
Wydane: (2019-01-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
od: Ryota Otoshi, i wsp.
Wydane: (2020-03-01)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
od: Ian Pavord, i wsp.
Wydane: (2023-04-01)